Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104610 | 0.86 | PDE4B (0.53) | KDM1APDE4BGPR119NAMPTMEN1 | |
| SCHEMBL5371252 | 0.83 | HTR2C (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL5371256 | 0.83 | HTR2C (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL5365894 | 0.81 | PDE4B (0.48) | KDM1APDE4BGPR119USP30PDE4A | |
| SCHEMBL23228721 | 0.81 | GPR119 (0.50) | KDM1APDE4BGPR119NAMPTMEN1 | |
| SCHEMBL29691266 | 0.80 | GPR119 (0.51) | ALDH1A1LMNAGPR119NAMPTMEN1 | |
| SCHEMBL23209949 | 0.80 | GPR119 (0.51) | ALDH1A1LMNAGPR119NAMPTMEN1 | |
| SCHEMBL23228679 | 0.79 | GPR119 (0.50) | ALDH1A1LMNAGPR119NAMPTMEN1 | |
| SCHEMBL5373375 | 0.79 | PDK4 (0.52) | KDM1ANAMPT | |
| SCHEMBL5373377 | 0.79 | PDK4 (0.52) | KDM1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | KDM1A 1633/4885PDE4B 734/4885ALDH1A1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.